Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume -, Issue -, Pages 201922207
Publisher
Proceedings of the National Academy of Sciences
Online
2020-05-19
DOI
10.1073/pnas.1922207117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
- (2019) William S. Chen et al. EUROPEAN UROLOGY
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The role of lineage plasticity in prostate cancer therapy resistance
- (2019) Himisha Beltran et al. CLINICAL CANCER RESEARCH
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
- (2019) Daniel E. Spratt et al. CLINICAL CANCER RESEARCH
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
- (2019) Florian Handle et al. Scientific Reports
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Cellular plasticity and the neuroendocrine phenotype in prostate cancer
- (2018) Alastair H. Davies et al. Nature Reviews Urology
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer
- (2018) Channing Paller et al. PROSTATE
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
- (2017) Shuang G. Zhao et al. JAMA Oncology
- Functional characterization of somatic mutations in cancer using network-based inference of protein activity
- (2016) Mariano J Alvarez et al. NATURE GENETICS
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer
- (2016) Dingxiao Zhang et al. Nature Communications
- The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
- (2016) Jennifer L. Bishop et al. Cancer Discovery
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A basal stem cell signature identifies aggressive prostate cancer phenotypes
- (2015) Bryan A. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance
- (2015) D. T. Miyamoto et al. SCIENCE
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling
- (2013) A. Schroeder et al. CANCER RESEARCH
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
- (2012) Gary Hudes et al. INVESTIGATIONAL NEW DRUGS
- Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells
- (2012) Toni Celià-Terrassa et al. JOURNAL OF CLINICAL INVESTIGATION
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Pluripotent Stem Cell Reprogramming Factors by Prostate Tumor Initiating Cells
- (2010) Kyung-Mi Bae et al. JOURNAL OF UROLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- (2009) David A. Barbie et al. NATURE
- Linking the p53 tumour suppressor pathway to somatic cell reprogramming
- (2009) Teruhisa Kawamura et al. NATURE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search